Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in predictive diagnostics and precision medicine is pleased to announce outstanding results for its world-first diagnostic blood test to identify esophageal adenocarcinoma, PromarkerEso.
The results from the Company’s clinical validation study will be presented today at the 20th annual ISDE World Congress for Esophageal Diseases, in Edinburgh, Scotland, held 22-24 September 2024. Esophageal adenocarcinoma (EAC) is the predominant type of esophageal cancer in North America, Australia and Europe , and 1-2% of western population are considered at-risk for developing this cancer2.
The prevalence of EAC has increased dramatically worldwide, with a six-fold increase over the last 40 years, and it has become the 6th leading cause of cancer-related death and 7th most common cancer, now affecting more than 600,000 people globally each year . Proteomics International’s PromarkerEso blood test utilises glycoprotein biomarkers—‘fingerprints’ in the blood—to screen for EAC. In this clinical validation study 165 samples (N=66 EAC; N=99 healthy controls) from the Victoria Cancer Biobank were analysed to determine which individuals had EAC and which did not.
The results demonstrated accuracy of 94% and an AUC of 0.93, indicating outstanding diagnostic performance for identifying patients with EAC. The latest study also included assessment of the refined PromarkerEso test on a previously analysed cohort (Ochsner, USA), which also resulted in strong diagnostic accuracy. These new results build on the Company’s previous findings which enabled development of the prototype test [ASX: 8 September 2023] and validationProteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in predictive diagnostics and precision medicine is pleased to announce outstanding results for its world-first diagnostic blood test to identify esophageal adenocarcinoma, PromarkerEso.
